COX-2 inhibitors with a methylsulfoxide pharmacophore

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 5, 2005, Pages 617-620

  Chung, Shin ^a  

^a AmorePacific Corporation   (South Korea)

Author keywords

Cardiovascular safety; Cyclooxygenase 2 (COX 2); Gastrointestinal safety; Prodrug

Indexed keywords

4 PYRONE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYL SULFOXIDE; ETORICOXIB; KETOPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

ADENOMA; ADENOMATOUS POLYP; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; PHARMACOPHORE;

EID: 19044396662     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.5.617     Document Type: Article

References (10)

1. PSATY BM, FURBERG CD: COX-2 inhibitors - lessons in drug safety. N. Engl. J. Med. (2005) 352(11):1133-1135.
2. CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296(5567):539-541.
3. CATELLA-LAWSON F, MCADAM B et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharm. Exp. Ther. (1999) 289(2):735-741.
4. AW T-J, HAAS SJ, LIEW DL: Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med. (2005) 165(5):490-496.
5. MOH JH, CHOI YH et al.: A prodrug approach to COX-2 inhibitors with methylsulfone. Bioorg. Med. Chem. Lett. (2004) 14(7):1757-1760.
6. CATURLA F, JIMENEZ J-M et al.: Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors. J. Med. Chem. (2004) 47(15):3874-3886.
7. RIENDEAU D. PERCIVAL MD, BRIDEAU C et al.: Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharm. Exp. Ther. (2001) 296(2):558-566.
8. ROLF C. ENGSTROM B et al.: Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (1999) 38(6):564-567.
9. DEGNER F, SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Ther. (2000) 22(4):400-410.
10. CHUNG S, LIM KM, SHIN SS: Profiles of COX-2 inhibitors: present and future. Expert Opin. Ther. Patents (2005) 15(1):9-32.